Comparison of the effects of Ibandronate and Bonefos on non-small cell lung cancer with bone metastases

Chinese Journal of Clinical Oncology

Volumn 35, Issue 6, 2008, Pages 310-312

  Guo, Chen ^a   Guo, Qisen ^a   Qi, Jielin ^a   Liu, Qun ^a   Wu, Ning ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Bone metastasis; Bonefos; Chemotherapy; Ibandronate; Non small cell lung cancer(NSCLC)

Indexed keywords

CISPLATIN; CLODRONIC ACID; IBANDRONIC ACID;

ANALGESIA; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; TREATMENT RESPONSE;

EID: 77951763518     PISSN: 16727118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Coleman RE. Bisphosphonates: clinical experience [J]. Oncologist, 2004, 9 Suppl 4: 14-27
2. Sohara Y, Shimada H, DeClerck YA. Mechanisms of bone invasion and metastasis in human neuroblastoma [J]. Cancer Lett J, 2005, 228(1-2): 203-209 (Pubitemid 41188443)
3. Zheng Y, Zhou H, Brennan K, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the and-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis[J]. Bone, 2007, 40(2): 471-478 (Pubitemid 46070226)
4. Antràs L, Smith M, Neary MP, et al. Presented at the 8th and Valedictory Workshop on Bisphosphonates [M]. Davos Switzerland, 2006. 22-24
5. Kiagia M, Karapanagiotou E, Charpidou A, et al. Rapid infusion of ibandronate in lung cancer patients with bone metastases [J]. Anticancer Res, 2006, 26(4B): 3133-3136 (Pubitemid 44161812)
6. Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial [J]. Clin Drug Investig, 2006, 26(6): 315-322 (Pubitemid 43876565)
7. Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis[J]. Bone, 2005, 37(5): 651-654
8. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study [J]. Ann Rheum Dis, 2006, 65(5): 654-661
9. Bergner R, Henrich D, Hoffmann M, et al. High bone-binding capacity of ibandronate in hemodialysis patients [J]. Int J Clin Pharmacol Res, 2005, 25(3): 123-131 (Pubitemid 41719436)
10. Kurth AA, Kim SZ, Shea M, et al. Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis[J]. J Bone Miner Metab, 2007, 25 (2): 86-92 (Pubitemid 46328663)